Drugmaker Pfizer, emboldened by positive results from an immunization trial for its bivalent respiratory syncytial virus 9RSV) vaccine candidate, will be seeking FDA approval for the vaccine this year, the company said this week.

Pfizer will be ending enrollment in the study and will seek approval before the end of the calendar year.